OncoSec Medical Inc (ONCS) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $6. Rodman & Renshaw advised their investors in a research report released on Jul 21, 2016.
OncoSec Medical Inc opened for trading at $1.64 and hit $1.67 on the upside on Wednesday, eventually ending the session at $1.64, with a gain of 0.61% or 0.01 points. The heightened volatility saw the trading volume jump to 28,936 shares. Company has a market cap of $29 M.
In a different news, on Oct 19, 2015, Avtar S Dhillon (director) purchased 10,000 shares at $4.36 per share price. According to the SEC, on Oct 19, 2015, Sheela Mohan-peterson (Chief Legal Officer) purchased 520 shares at $4.24 per share price. On Oct 19, 2015, Punit Dhillon (CEO) purchased 10,000 shares at $4.23 per share price, according to the Form-4 filing with the securities and exchange commission.
OncoSec Medical Incorporated is a biotechnology company focused on designing developing and commercializing gene therapies therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types. The Company’s technology includes property relating to its ImmunoPulse delivery technology. The Company’s ImmunoPulse is an electroporation delivery device that the Company uses in combination with its therapeutic product candidates including deoxyribonucleic acid (DNA) plasmids that encode for immunologically active agents to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. Its electroporation devices consist of an electrical pulse generator and disposable applicators. The Company’s ImmunoPulse product candidates are based on its DNA based immunotherapy technology.